Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 23/7/2018
SIETES contiene 92430 citas

 1 a 20 de 40 siguiente >>
Presentar resultados
Seleccionar todas
2. Cita con resumen
Engel P, Almas MF, De Bruin ML, Starzyk K, Blackburn S, Dreyer AN. Lessons learned on the design and the conduct of Post-Authorization Safety Studies: review of 3 years of PRAC oversight. Br J Clin Pharmacol 2017;83:884-93. [Ref.ID 101970]
3.Tiene citas relacionadas Cita con resumen
Eichler H-G, Hurts H, Broich K, Rasi G. Drug regulation and pricing — Can regulators influence affordability?. N Engl J Med 2016;374:1807-9. [Ref.ID 100113]
5.Tiene citas relacionadas
Rothwell PM. Blood pressure in acute stroke: which questions remain?. Lancet 2015;385:582-5. [Ref.ID 98797]
6. Cita con resumen
Duijnhoven RG, Straus SMJM, Raine JM, de Boer A, Hoes AW, De Bruin ML. Number of patients studied prior to approval of new medicines: database analysis. PLOS Medicine 2013;10:1. [Ref.ID 95146]
7.Tiene citas relacionadas Cita con resumen
Gale E. Post-marketing studies of new insulins: science or sales?. BMJ 2012;344:24-7. [Ref.ID 93248]
8.Tiene citas relacionadas Cita con resumen
10. Cita con resumen
Shaughnessy A. Old drugs, new tricks. BMJ 2011;342:360-1. [Ref.ID 90211]
11. Cita con resumen
Strahlman E, Rockhold F, Freeman A. Public disclosure of clinical research. Lancet 2009;373:1319-20. [Ref.ID 85657]
13. Cita con resumen
Clark DWJ, Coulter DM, Besag FMC. Randomized controlled trials and assessment of drug safety. Drug Saf 2008;31:1057-61. [Ref.ID 84722]
14. Cita con resumen
Cohen AF. Methods in clinical pharmacology - a tale of two worlds. Br J Clin Pharmacol 2008;66:585-7. [Ref.ID 84390]
15. Cita con resumen
Lenzer J. Truly independent research?. BMJ 2008;337:602-6. [Ref.ID 83973]
16. Cita con resumen
Cooper AJP, Lettis S, Chapman CL, Evans SJW, Waller PC, Shakir S, Payvandi N, Murray AB. Developing tools for the safety specification in risk management plans: lessons learned from a pilot project. Pharmacoepidemiol Drug Saf 2008;17:45-454. [Ref.ID 82982]
17. Cita con resumen
Anónimo. New rimonabant recommendations made in Argentina. Scrip 2007;3285:16. [Ref.ID 80725]
18. Cita con resumen
Day RO, Williams KM. Open-label extension studies: do they provide meaningful information on the safety of new drugs?. Drug Saf 2007;30:93-105. [Ref.ID 79290]
19. Cita con resumen
Psaty BM, Weiss NS. NSAID trials and the choice of comparators - questions of public health importance. N Engl J Med 2007;356:328-30. [Ref.ID 78942]
20.Tiene citas relacionadas Cita con resumen
Hiatt WR. Observational studies of drug safety - Aprotinin and the absence of transparency. N Engl J Med 2006;355:2171-3. [Ref.ID 78557]
Seleccionar todas
 1 a 20 de 40 siguiente >>